{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:17:48Z","timestamp":1782422268293,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.medcli.2024.01.026","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T10:04:44Z","timestamp":1713261884000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"163","author":[{"given":"Lorenzo","family":"Cantarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Guti\u00e9rrez Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Leache Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Carlos","family":"Sainz Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Erviti Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Guti\u00e9rrez Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Julia","family":"Nazco Casariego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.01.026_bib0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pop.2020.08.010","article-title":"Autosomal dominant polycystic kidney disease","volume":"47","author":"Perumareddi","year":"2020","journal-title":"Prim Care"},{"key":"10.1016\/j.medcli.2024.01.026_bib0145","doi-asserted-by":"crossref","unstructured":"Cordido A, Besada-cerecedo L, Garc\u00eda-gonz\u00e1lez MA. The genetic and cellular basis of autosomal dominant polycystic kidney disease\u2014a primer for clinicians. 2017; 5:1\u20138. https:\/\/doi.org\/10.3389\/fped.2017.00279.","DOI":"10.3389\/fped.2017.00279"},{"key":"10.1016\/j.medcli.2024.01.026_bib0150","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41390-020-0942-2","article-title":"Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression","volume":"89","author":"Raina","year":"2021","journal-title":"Pediatr Res"},{"key":"10.1016\/j.medcli.2024.01.026_bib0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"Van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.medcli.2024.01.026_bib0160","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"86","author":"Spithoven","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2024.01.026_bib0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000449394","article-title":"Clinical manifestation and management of ADPKD in Western Countries","volume":"2","author":"Sommerer","year":"2016","journal-title":"Kidney Dis"},{"key":"10.1016\/j.medcli.2024.01.026_bib0170","unstructured":"Santamar\u00eda-olmo R, Gorostidi-p\u00e9rez M. Presi\u00f3n arterial y progresi\u00f3n de la enfermedad renal cr\u00f3nica. 2013; 5:4\u201311. https:\/\/doi.org\/10.3265\/NefroPlus.pre2013.May.12105."},{"key":"10.1016\/j.medcli.2024.01.026_bib0175","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.01.026_bib0180","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10157-021-02083-y","article-title":"Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan","volume":"25","author":"Muto","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.medcli.2024.01.026_bib0185","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2024.01.026_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-021-02607-4","article-title":"Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN\u00ae dataset","volume":"22","author":"Thomas","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.medcli.2024.01.026_bib0195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/TCRM.S286952","article-title":"Safety profile of tolvaptan in the treatment of autosomal dominant polycystic kidney disease","volume":"17","author":"Bellos","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.medcli.2024.01.026_bib0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/IJNRD.S125942","article-title":"Tolvaptan in the treatment of autosomal dominan","volume":"11","author":"Sans-atxer","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.medcli.2024.01.026_bib0205","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10157-021-02100-0","article-title":"Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance","volume":"25","author":"Mochizuki","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.medcli.2024.01.026_bib0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40265-019-1056-1","article-title":"Tolvaptan: a review in autosomal dominant polycystic kidney disease","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.medcli.2024.01.026_bib0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/1386207322666191203092715","article-title":"Effectiveness of tolvaptan in the treatment for patients with autosomal dominant polycystic kidney disease: a meta-analysis","volume":"23","author":"Xie","year":"2020","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.medcli.2024.01.026_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.nefroe.2023.04.002","article-title":"The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis","author":"Li","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.medcli.2024.01.026_bib0225","doi-asserted-by":"crossref","unstructured":"M\u00fcller R, Messchendorp AL, Birn H, Capasso G, Gall EC, Devuyst O, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. 2022;37:825\u201339. https:\/\/doi.org\/10.1093\/ndt\/gfab312.","DOI":"10.22141\/2307-1257.11.1.2022.357"},{"key":"10.1016\/j.medcli.2024.01.026_bib0230","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nefro.2021.05.009","article-title":"Poliquistosis renal autos\u00f3mica dominante Documento de consenso de poliquistosis","volume":"42","author":"Ars","year":"2022","journal-title":"Nefrologia"},{"key":"10.1016\/j.medcli.2024.01.026_bib0235","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000506288","article-title":"Executive summary: clinical practice guideline for autosomal dominant polycystic kidney disease in China","volume":"6","author":"Mei","year":"2020","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.medcli.2024.01.026_bib0240","first-page":"7","article-title":"Safety and tolerability of tolvaptan in an autosomal dominant polycystic kidney disease spanish cohort: a real-world experience","volume":"12","author":"Guerra-torres","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.medcli.2024.01.026_bib0245","first-page":"1","article-title":"Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease","author":"Naranjo","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.medcli.2024.01.026_bib0250","doi-asserted-by":"crossref","first-page":"801","DOI":"10.21873\/invivo.13144","article-title":"Efficacy and safety of tolvaptan for patients with autosomal dominant polycystic kidney disease in real-world practice: a single institution retrospective study","volume":"805","author":"Masuda","year":"2023","journal-title":"In Vivo"},{"key":"10.1016\/j.medcli.2024.01.026_bib0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000491022","article-title":"A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression","volume":"48","author":"Magistroni","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.medcli.2024.01.026_bib0260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2024.01.026_bib0265","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s40620-022-01286-0","article-title":"Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method","volume":"35","author":"Miquel","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.medcli.2024.01.026_bib0270","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s10157-022-02192-2","article-title":"Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease","volume":"26","author":"Akihisa","year":"2022","journal-title":"Clin Exp Nephrol"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324001647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324001647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:03:54Z","timestamp":1719713034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324001647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0025775324001647"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.01.026","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}